JP2024517355A - 血管内皮炎の治療において使用するための中間分子量ヘパリン - Google Patents

血管内皮炎の治療において使用するための中間分子量ヘパリン Download PDF

Info

Publication number
JP2024517355A
JP2024517355A JP2023570373A JP2023570373A JP2024517355A JP 2024517355 A JP2024517355 A JP 2024517355A JP 2023570373 A JP2023570373 A JP 2023570373A JP 2023570373 A JP2023570373 A JP 2023570373A JP 2024517355 A JP2024517355 A JP 2024517355A
Authority
JP
Japan
Prior art keywords
molecular weight
weight heparin
intermediate molecular
vwf
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517355A5 (enExample
Inventor
シン ボーガル，パーヴィンダー
Original Assignee
グリコス バイオメディカル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコス バイオメディカル リミテッド filed Critical グリコス バイオメディカル リミテッド
Publication of JP2024517355A publication Critical patent/JP2024517355A/ja
Publication of JP2024517355A5 publication Critical patent/JP2024517355A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023570373A 2021-05-14 2022-05-16 血管内皮炎の治療において使用するための中間分子量ヘパリン Pending JP2024517355A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2106972.9A GB202106972D0 (en) 2021-05-14 2021-05-14 Medium molecular weight heparin
GB2106972.9 2021-05-14
PCT/EP2022/063222 WO2022238587A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy

Publications (2)

Publication Number Publication Date
JP2024517355A true JP2024517355A (ja) 2024-04-19
JP2024517355A5 JP2024517355A5 (enExample) 2025-05-26

Family

ID=76550734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570373A Pending JP2024517355A (ja) 2021-05-14 2022-05-16 血管内皮炎の治療において使用するための中間分子量ヘパリン

Country Status (8)

Country Link
US (1) US20240245718A1 (enExample)
EP (1) EP4337225A1 (enExample)
JP (1) JP2024517355A (enExample)
CN (1) CN117915923A (enExample)
AU (1) AU2022273186A1 (enExample)
CA (1) CA3219993A1 (enExample)
GB (1) GB202106972D0 (enExample)
WO (1) WO2022238587A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024381335A1 (en) 2023-11-17 2026-05-21 Glycos Biomedical Ltd. Medium molecular weight heparin
GB202407360D0 (en) 2024-05-23 2024-07-10 Glycos Biomedical Ltd Functionalised medium molecular weight heparin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020504185A (ja) * 2017-01-11 2020-02-06 フィタゴラス ベー．ヴェー．Ｆｙｔａｇｏｒａｓ Ｂ．Ｖ． 中分子量ヘパリン
WO2020231830A1 (en) * 2019-05-16 2020-11-19 Exthera Medical Corporation Method for modulating endothelial glycocalyx structure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1045532A1 (zh) * 1999-06-30 2002-11-29 Hamilton Civic Hospitals Research Development, Inc. 抑制与凝结有关凝结因子的肝素成份
JP2021155334A (ja) * 2018-05-01 2021-10-07 学校法人近畿大学 中分子ヘパリンまたは中分子ヘパリンのアミノ酸誘導体を含む医薬組成物
WO2022016098A1 (en) * 2020-07-17 2022-01-20 Xostem Ip, Inc. Compositions and methods for treatment of inflammatory and thromboinflammatory disorders using modified exosomes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020504185A (ja) * 2017-01-11 2020-02-06 フィタゴラス ベー．ヴェー．Ｆｙｔａｇｏｒａｓ Ｂ．Ｖ． 中分子量ヘパリン
WO2020231830A1 (en) * 2019-05-16 2020-11-19 Exthera Medical Corporation Method for modulating endothelial glycocalyx structure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
[ONLINE], vol. [検索日 2026.04.14], JPN6026016052, 2020, pages 2, ISSN: 0005849644 *
CIRCULATION, vol. 93, no. 5, JPN6026016051, 1996, pages 992 - 999, ISSN: 0005849643 *

Also Published As

Publication number Publication date
CN117915923A (zh) 2024-04-19
US20240245718A1 (en) 2024-07-25
EP4337225A1 (en) 2024-03-20
GB202106972D0 (en) 2021-06-30
WO2022238587A1 (en) 2022-11-17
CA3219993A1 (en) 2022-11-17
AU2022273186A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
van Lier et al. Experimental human endotoxemia as a model of systemic inflammation
Best et al. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
KR20140053881A (ko) 모세관 누출의 예방 및 치료를 위한 수술 동안 투여되는 프로스타시클린 및 그 유사체
JP2001506603A (ja) 抗―Ｘａ活性を有する化合物及び血小板凝集拮抗剤化合物を含有する製薬組成物
US20240245718A1 (en) Medium molecular weight heparin for use in the treatment of endotheliopathy
Topsakal et al. Effects of chronic obstructive pulmonary disease on coronary atherosclerosis
Fealy et al. A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration
Rikken et al. Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction–A post hoc analysis of the cel-02 phase IIa study
Jankowska-Sanetra et al. Incidence and course of acute coronary syndrome cases after the first wave of the COVID-19 pandemic
WO2024105271A1 (en) Preparation of medium molecular weight heparin
Lunetta et al. Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease
Ades et al. Factor XI inhibitors: potential role in end-stage kidney disease
HK40109661A (en) Medium molecular weight heparin for use in the treatment of endotheliopathy
Dixon et al. Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery
Tsipis et al. Novel oral anticoagulants in peripheral arterial and coronary artery disease
Sharma et al. Tranexamic acid leads to paradoxical coagulation changes during cardiac surgery: a pilot rotational thromboelastometry study
JP2025537781A (ja) 中間分子量ヘパリンの調製
Bendel et al. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation
WO2025106117A1 (en) Medium molecular weight heparin
Uğuz et al. In vitro analysis of the effect of contrast agents on the antiaggregant effects of P2Y12 inhibitors
WO2025245445A1 (en) Functionalised medium molecular weight heparin
Shi et al. Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy
Armstrong et al. Pharmacology of hemostasis and thrombosis
Wang et al. Stuck Between a Rock and a Hard Place: Anticoagulation in End-Stage Kidney Disease Patients With Atrial Fibrillation
Ren et al. A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260727